Not recruiting
Neoplasm
Not recruitingStudy of PRS-344/S095012 and obinutuzumab combination for patients with solid tumors - First human trial to evaluate safety and effectiveness
Registered drugNo placebo
Study of PRS-344/S095012 and obinutuzumab combination for patients with solid tumors - First human trial to evaluate safety and effectiveness
Registered drugNo placebo
- Disease:Neoplasm
- Substances:ObinutuzumabPRS-344
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Obinutuzumab


